Daiichi Sankyo Nordics

Daiichi Sankyo Nordics company information, Employees & Contact Information

Daiichi Sankyo Nordics is a part of Daiichi Sankyo, a global pharmaceutical company based in Japan. We aim at contributing to timely access of new treatment options to give more people impacted by cancer more time with their loved ones. Because we know that every moment matters. With more than 100 years of scientific expertise, Daiichi Sankyo creates innovative pharmaceuticals, healthcare solutions and information for people with cancer as well as other diseases with high unmet medical needs. In the Nordics our focus is oncology. We want to create value through strong collaboration with healthcare professionals, patients, and stakeholders. Daiichi Sankyo Nordics combines Japanese thoroughness and innovation with Nordic openness, reliability, and dialogue. We put patients at heart in everything we do. In Daiichi Sankyo Nordics, we are growing fast. We have one of the most exciting product pipelines and even more ambitious plans. For these reasons, we are continuously looking for new talents that are driven by a passion to deliver best solutions to healthcare professionals who aim to provide their patients with the best possible therapy. At Daiichi Sankyo we put great emphasis on HOW we do things and not only WHAT we do, and our culture is characterized by creating a safe and caring environment with focus on Collaboration, Curiosity and Trust. People and culture development is present every day. Daiichi Sankyo is operating in 24 countries and employs 16.000 people around the world. Our Nordic headquarter is located in Copenhagen and we are a growing and dedicated team. For more information, please visit www.nordics.daiichi-sankyo.eu.

Company Details

Employees
37
Founded
-
Address
Amagerfælledvej 106, Copenhagen,capital Region Of Denmark 2300,denmark
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
La Valletta.
HQ
Copenhagen, Capital Region of Denmark
Looking for a particular Daiichi Sankyo Nordics employee's phone or email?

Daiichi Sankyo Nordics Questions

News

Markus Kosch: Patient Safety Day at Dalichi Sankyo Europe - Oncodaily

Markus Kosch: Patient Safety Day at Dalichi Sankyo Europe Oncodaily

Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C - BioSpace

Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C BioSpace

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C - Yahoo Finance

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C Yahoo Finance

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC - OncLive

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC OncLive

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe - PMLiVE

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe PMLiVE

ENDEAVOUR Lung Cancer Program Forms International Teams to Initiate Four Collaborative Projects Focused on Advancing Patient Care - Business Wire

ENDEAVOUR Lung Cancer Program Forms International Teams to Initiate Four Collaborative Projects Focused on Advancing Patient Care Business Wire

Julia Ruthus: Examining breast cancer care across the major five European countries - Oncodaily

Julia Ruthus: Examining breast cancer care across the major five European countries Oncodaily

AstraZeneca and Daiichi’s breast cancer drug gets EU backing - The Japan Times

AstraZeneca and Daiichi’s breast cancer drug gets EU backing The Japan Times

Esperion and Daiichi Sankyo Europe amend partnership - Pharmaceutical Technology

Esperion and Daiichi Sankyo Europe amend partnership Pharmaceutical Technology

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025 - European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025 European Medicines Agency

How Daiichi Sankyo Europe drives growth with digital and analytics - McKinsey & Company

How Daiichi Sankyo Europe drives growth with digital and analytics McKinsey & Company

Daiichi Sankyo: Turning Customer Insights into Impact - Veeva

Daiichi Sankyo: Turning Customer Insights into Impact Veeva

Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs - BioPharm International

Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs BioPharm International

Masahiro Kato steps in as Managing Director of Daiichi Sankyo Europe - BioSpectrum Asia

Masahiro Kato steps in as Managing Director of Daiichi Sankyo Europe BioSpectrum Asia

Daiichi Sankyo bolsters oncology portfolio with $1bn site expansion - BioProcess International

Daiichi Sankyo bolsters oncology portfolio with $1bn site expansion BioProcess International

Change in Leadership at Daiichi Sankyo Europe - Business Wire

Change in Leadership at Daiichi Sankyo Europe Business Wire

Markus Kosch: Breast Cancer remains a global health challenge - Oncodaily

Markus Kosch: Breast Cancer remains a global health challenge Oncodaily

Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit - BioSpace

Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit BioSpace

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation - Business Wire

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation Business Wire

Daiichi Sankyo at ASCO 2025: Markus Kosch on Advancing Patient Outcomes Through Scientific Innovation - Oncodaily

Daiichi Sankyo at ASCO 2025: Markus Kosch on Advancing Patient Outcomes Through Scientific Innovation Oncodaily

Julia Ruthus: What does holistic survivorship care in metastatic breast cancer look like? - Oncodaily

Julia Ruthus: What does holistic survivorship care in metastatic breast cancer look like? Oncodaily

Daiichi Sankyo joins Startup Creasphere's Program Powered by Plug and Play - PR Newswire

Daiichi Sankyo joins Startup Creasphere's Program Powered by Plug and Play PR Newswire

Daiichi study finds gender inequality in European cardiovascular care - Fierce Pharma

Daiichi study finds gender inequality in European cardiovascular care Fierce Pharma

Edoxaban Approved for AF, DVT/PE in Europe - respiratory-therapy.com

Edoxaban Approved for AF, DVT/PE in Europe respiratory-therapy.com

Esperion argues case for milestone from Daiichi Sankyo - The Pharma Letter

Esperion argues case for milestone from Daiichi Sankyo The Pharma Letter

Beyond Biotech podcast 47 - Labiotech.eu

Beyond Biotech podcast 47 Labiotech.eu

First-in-class cholesterol-lowering treatment NILEMDO ® ▼ and its combination with ezetimibe, NUSTENDI ® ▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk - Via TT

First-in-class cholesterol-lowering treatment NILEMDO ® ▼ and its combination with ezetimibe, NUSTENDI ® ▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk Via TT

AstraZeneca, Daiichi Sankyo withdraw application for lung cancer therapy - Pharmaceutical Technology

AstraZeneca, Daiichi Sankyo withdraw application for lung cancer therapy Pharmaceutical Technology

Esperion, Daiichi Sankyo Europe announce USD 125 million amendment to their collaboration, including... - Medical Dialogues

Esperion, Daiichi Sankyo Europe announce USD 125 million amendment to their collaboration, including... Medical Dialogues

Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany - Fierce Pharma

Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany Fierce Pharma

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement - Fierce Pharma

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement Fierce Pharma

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy - Reuters

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy Reuters

AI as Enterprise-Wide Enabler of Clinical Trial Innovation - with Leaders from Medable, Takeda, Sanofi, Novartis, and Daiichi Sankyo - Emerj Artificial Intelligence Research

AI as Enterprise-Wide Enabler of Clinical Trial Innovation - with Leaders from Medable, Takeda, Sanofi, Novartis, and Daiichi Sankyo Emerj Artificial Intelligence Research

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer - Yahoo Finance

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer Yahoo Finance

Daiichi's cholesterol meds get expanded nod for cutting CV risk in Europe - FirstWord Pharma

Daiichi's cholesterol meds get expanded nod for cutting CV risk in Europe FirstWord Pharma

Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom - Veeva

Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom Veeva

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer - PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu receives EU approval - PharmaTimes

AstraZeneca and Daiichi Sankyo’s Enhertu receives EU approval PharmaTimes

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer - PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer PMLiVE

Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit - Fierce Pharma

Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit Fierce Pharma

American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility in France to Complement Its U.S. Manufacturing - PR Newswire

American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility in France to Complement Its U.S. Manufacturing PR Newswire

Daiichi Sankyo’s technological revolution - Global Times

Daiichi Sankyo’s technological revolution Global Times

AstraZeneca, Daiichi pull dato-DXd lung cancer filing in EU - FirstWord Pharma

AstraZeneca, Daiichi pull dato-DXd lung cancer filing in EU FirstWord Pharma

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study - The Lancet

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study The Lancet

EU regulator backs AstraZeneca and Daiichi's lung cancer drug - Reuters

EU regulator backs AstraZeneca and Daiichi's lung cancer drug Reuters

Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia - PMLiVE

Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia PMLiVE

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors - Yahoo Finance

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors Yahoo Finance

AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3 - Fierce Biotech

AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3 Fierce Biotech

The Innovation, Care, and Compassion of Daiichi Sankyo – Part 2 - European Medical Journal

The Innovation, Care, and Compassion of Daiichi Sankyo – Part 2 European Medical Journal

Bayer’s Martin Hesse moves to Daiichi Sankyo Europe - PMLiVE

Bayer’s Martin Hesse moves to Daiichi Sankyo Europe PMLiVE

AstraZeneca, Daiichi's Enhertu approved in EU for HER2-mutant NSCLC - FirstWord Pharma

AstraZeneca, Daiichi's Enhertu approved in EU for HER2-mutant NSCLC FirstWord Pharma

New approval in Europe for Nilemdo and Nustendi - The Pharma Letter

New approval in Europe for Nilemdo and Nustendi The Pharma Letter

AstraZeneca and Daiichi Sankyo withdraw EU application for lung cancer drug - grafa.com

AstraZeneca and Daiichi Sankyo withdraw EU application for lung cancer drug grafa.com

EC approves Nilemdo™ (bempedoic acid) for lowering cholesterol - European Pharmaceutical Review

EC approves Nilemdo™ (bempedoic acid) for lowering cholesterol European Pharmaceutical Review

US, European pharma stocks steady after Trump's tariff move, Asia slips - Reuters

US, European pharma stocks steady after Trump's tariff move, Asia slips Reuters

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced lung cancer - PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced lung cancer PMLiVE

Daiichi Sankyo to market hypercholesterolemia treatment in Asia - BioSpectrum Asia

Daiichi Sankyo to market hypercholesterolemia treatment in Asia BioSpectrum Asia

Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid - BioSpace

Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid BioSpace

Daiichi Sankyo gets EU OK for Lixiana anticoagulant - PMLiVE

Daiichi Sankyo gets EU OK for Lixiana anticoagulant PMLiVE

Turalio: Why The EU Said No To The US-Approved Drug - Citeline News & Insights

Turalio: Why The EU Said No To The US-Approved Drug Citeline News & Insights

Daiichi Sankyo Closes Japan Research Subsidiary Asubio Pharma in R&D Overhaul - Genetic Engineering and Biotechnology News

Daiichi Sankyo Closes Japan Research Subsidiary Asubio Pharma in R&D Overhaul Genetic Engineering and Biotechnology News

Merck & Co to sell Daiichi Sankyo’s Lixiana in 13 European countries - The Pharma Letter

Merck & Co to sell Daiichi Sankyo’s Lixiana in 13 European countries The Pharma Letter

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024 - European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024 European Medicines Agency

First-in-class cholesterol-lowering treatment NILEMDO ® ▼ and its combination with ezetimibe, NUSTENDI ® ▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk - NTB Kommunikasjon

First-in-class cholesterol-lowering treatment NILEMDO ® ▼ and its combination with ezetimibe, NUSTENDI ® ▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk NTB Kommunikasjon

Esperion Therapeutics, Inc. SEC 10-K Report - TradingView

Esperion Therapeutics, Inc. SEC 10-K Report TradingView

ENHERTU ® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy - Via TT

ENHERTU ® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy Via TT

NILEMDO ® Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment - NTB Kommunikasjon

NILEMDO ® Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment NTB Kommunikasjon

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe - MultiVu

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe MultiVu

Top Daiichi Sankyo Nordics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant